Rhabdomyosarkom
Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.
| ID | DIS-RHABDOMYOSARCOMA |
|---|---|
| Art | Erkrankung |
| Aliase | Alveolar-Rhabdomyosarkom (ARMS)Embryonales Rhabdomyosarkom (ERMS)RMSSarkom der SkelettmuskulaturdifferenzierungРабдоміосаркома |
| Status | reviewed 2026-05-19 | pending_clinical_signoff |
| Erkrankungen | None declared |
| Quellen | SRC-ESMO-SARCOMA-2024 |
Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.
| icd_o_3_morphology | 8910/3 |
|---|---|
| icd_o_3_topography | ["C49"] |
| icd_10 | C49.9 |
| who_classification | WHO Weichgewebe + Knochentumore 5 ed (2020): Embryonal RMS, Alveolar RMS (Alveolarer RMS), Spindelzelle/Schlacker RMS und peomorphes RMS |
Anmerkungen
PAX3-FOXO1 fusion status is the strongest single prognostic marker. EpSSG (European) and COG (North American) cooperatives study risk- adapted regimens. Fusion-positive ARMS now receives intensified treatment; fusion-negative ARMS behaves more like ERMS. Surveillance in Costello + LFS + DICER1 carriers: abdominal/pelvic US q3-6 mo to age 8-10; symptom-driven imaging for soft-tissue mass at any age.
Verwendet von
Erkrankung
DIS-NEUROBLASTOMA- Neuroblastom